- Home
- FOLD vs HAFN Comparison
FOLD vs HAFN Comparison
Compare FOLD & HAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- HAFN
- Stock Information
- Founded
- FOLD 2002
- HAFN 2012
- Country
- FOLD United States
- HAFN Singapore
- Employees
- FOLD N/A
- HAFN N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- HAFN
- Sector
- FOLD Health Care
- HAFN
- Exchange
- FOLD Nasdaq
- HAFN Nasdaq
- Market Cap
- FOLD 2.9B
- HAFN 2.7B
- IPO Year
- FOLD 2007
- HAFN N/A
- Fundamental
- Price
- FOLD $6.32
- HAFN $5.47
- Analyst Decision
- FOLD Strong Buy
- HAFN Strong Buy
- Analyst Count
- FOLD 10
- HAFN 1
- Target Price
- FOLD $26.89
- HAFN $6.50
- AVG Volume (30 Days)
- FOLD 4.2M
- HAFN 1.1M
- Earning Date
- FOLD 07-31-2025
- HAFN 08-27-2025
- Dividend Yield
- FOLD N/A
- HAFN 16.72%
- EPS Growth
- FOLD N/A
- HAFN N/A
- EPS
- FOLD N/A
- HAFN 1.20
- Revenue
- FOLD $571,160,000.00
- HAFN $2,631,664,000.00
- Revenue This Year
- FOLD $19.97
- HAFN N/A
- Revenue Next Year
- FOLD $22.92
- HAFN $1.07
- P/E Ratio
- FOLD N/A
- HAFN $4.38
- Revenue Growth
- FOLD 32.29
- HAFN N/A
- 52 Week Low
- FOLD $5.51
- HAFN $3.61
- 52 Week High
- FOLD $12.65
- HAFN $8.26
- Technical
- Relative Strength Index (RSI)
- FOLD 55.44
- HAFN N/A
- Support Level
- FOLD $6.06
- HAFN N/A
- Resistance Level
- FOLD $6.40
- HAFN N/A
- Average True Range (ATR)
- FOLD 0.28
- HAFN 0.00
- MACD
- FOLD 0.01
- HAFN 0.00
- Stochastic Oscillator
- FOLD 49.44
- HAFN 0.00
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.